Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06224309 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Preliminary Assessment of [18F]BL40 in PET/CT Scans

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 10 to 30 Primary completion date: Sep 15, 2024 to Mar 15, 2027 · Primary endpoints: details revised at 1 of 5 entries · Sponsor refiled this as recruiting (was completed) · 5 more Show 8 more changesShow less
    • Primary completion date: Sep 15, 2024 to Mar 15, 2027
    • Primary endpoints: details revised at 1 of 5 entries
    • Sponsor refiled this as recruiting (was completed)
    • Completion date: Feb 14, 2025 to Sep 15, 2027
    • Interventions: 18F-BL40 PET/CT (Diagnostic Test), 18F-FDG PET/CT (Diagnostic Test), Routine Blood Draw - Phase 1 only (Diagnostic Test) to 18F-BL40 PET/CT (Diagnostic Test), 18F-FDG PET/CT (Diagnostic Test), Routine Blood Draw - Phase 1 only (Diagnostic Test)
    • Eligibility criteria shortened, about 146 words
    • Secondary endpoints: details revised at 3 of 5 entries
    • Site details revised
  2. Trial status: Not Yet Recruiting to Completed Enrollment target: estimated 30 to confirmed 10 · Primary completion date changed from estimate of Dec 2024 to Sep 15, 2024 · Study completion date changed from estimate of Oct 2025 to Feb 14, 2025 · 2 morev3 Show 5 more changesShow less
    • Enrollment target: estimated 30 to confirmed 10
    • Primary completion date changed from estimate of Dec 2024 to Sep 15, 2024
    • Study completion date changed from estimate of Oct 2025 to Feb 14, 2025
    • Start date changed from estimate of May 2024 to Jun 10, 2024
    • Site contact updated
  3. Primary endpoints: 4 to 5v2 See this version in full on ClinicalTrials.gov ↗
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
British Columbia Cancer Agency
49 trials monitored
See 5 trials at risk
Leukemia
2,566 trials monitored
See 143 trials at risk
Non-Hodgkin Lymphoma
1,517 trials monitored
See 84 trials at risk
Multiple Myeloma
1,231 trials monitored
See 77 trials at risk
and 3 more diseases
CXCR4 is type of receptor that has been detected in more than twenty different subtypes of cancers. Most of these cancers are associated with negative symptoms that worsen over time resulting in great disability and poor function. There is a need for novel tracers to image CXCR4-expressing tumors for better detection, staging, and monitoring of aggressive cancers without the need for invasive biopsy procedures that may not always properly capture the extent of a patient's disease. This study looks to assess the safety and efficacy of a novel radiopharmaceutical known as 18F-BL40 through its use in a PET/CT scan. Participants will receive 2 PET/CT scans: 18F-BL40 and 18F-FDG as part of this study.
Trial Details
NCT Number NCT06224309
Lead Sponsor British Columbia Cancer Agency
Conditions Diffuse Large B-cell Lymphoma, Multiple Myeloma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Waldenström Macroglobulinemia
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov